Inside Biopharma’s 2025 Deal Wave: Record Licensing, Big Pharma M&A and a Frozen IPO Market -( $JPM $IBB $XBI $LLY $MRK $NVS $PFE ) by John F. Heerdink, Jr. 6 hours ago 24Views 0Likes Biopharma spent 2025 behaving like a sector that has finally read the fine print on the cost of capital—and decided to let someone else pick up the bar tab. Licensing and M&A stepped into the role IPOs used to play, and did… Read more
